NEW YORK (360Dx) – Cancer detection firm Oncimmune today announced the first distribution deals for its autoantibody-based lung cancer test.
Under the terms of the deals, Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune’s EarlyCDTLung cancer test in those countries. The agreements allow for the sale of the test as a central laboratory test while Oncimmune finishes the CE marking of a kit form of EarlyCDTLung.
The deal with Best Medical is for five years and takes effect May 1. The agreement with Dow Biomedica/Biodiscovery is initially for four years and also begins on May 1. Included in the agreements are minimum sales commitments starting in the second year, which will increase annually, amounting to £5.2 million ($6.7 million) in aggregate.
The first sales are expected to start in late 2017 or early 2018, said Oncimmune, which launched EarlyCDTLung in 2012 in the US.